サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1481965

抗体薬物複合体の北米市場：地域別分析 - 技術別、用途別、流通チャネル別、予測（～2030年）

North America Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel

出版日
ページ情報
英文 100 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.69円
抗体薬物複合体の北米市場：地域別分析 - 技術別、用途別、流通チャネル別、予測（～2030年）
出版日: 2024年03月04日
発行: The Insight Partners
ページ情報: 英文 100 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の抗体薬物複合体の市場規模は、2022年に36億5,981万米ドルに達し、2022～2030年にかけてCAGR 17.9%で成長し、2030年には136億8,158万米ドルに達すると予測されています。

ADCに対するFDA承認の増加が北米の抗体薬物複合体市場を後押し

2021年9月にNational Library of Medicineに掲載された記事「An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy」によると、2017年のADCの承認件数は8件で、2021年9月には11件に増加しました。FDAは2022年11月末まで、Lumoxitiを含むさらに数種類のADCを承認しています。世界では、50社以上のバイオ医薬品企業がADCの開発に携わっています。各社は主に血液がんや、肺がん、膀胱がん、婦人科腫瘍などの他のがん種を対象としています。さらに2021年6月、米国の投資銀行、Evercore ISIは、2030年までに各社がADCを年間200億米ドル以上で販売すると推定しました。ADCの承認と商業化の増加は、市場の大幅な成長につながっています。以下は、FDAが承認したADCのリストです。

  • 表1. FDA承認ADCリスト

会社名 商品名 ADC 製剤 がん種別 承認年

1 Pfizer/Wyeth Mylotarg Gemtuzumab ozogamicin Relapsed Acute Myelogenous Leukemia (AML) 2000; 2017

2 Seagen Genetics, Millennium/Takeda Adcetris Brentuximab vedotin Relapsed HL and Relapsed sALCL 2011

3 Genentech, Roche Kadcyla Trastuzumab emtansine HER2-positive Metastatic Breast Cancer (mBC) 2013

4 Pfizer/Wyeth Besponsa Inotuzumab ozogamicin Relapsed or Refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia 2017

5 Astrazeneca Lumoxiti Moxetumomab pasudotox Relapsed or refractory hairy cell leukaemia (HCL) in adults 2018

6 Genentech, Roche Polivy Polatuzumab vedotin-piiq Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 2019

7 Astellas/Seagen Genetics Padcev Enfortumab vedotin Metastatic urothelial cancer in adult who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy 2019

8 AstraZeneca/Daiichi Sankyo Enhertu Trastuzumab deruxtecan Metastatic HER2-positive breast cancer in adults, received two or more prior anti-HER2 based regimens 2019

9 Immunomedics Trodelvy Sacituzumab govitecan Metastatic triple-negative breast cancer (mTNBC) in adults, and patients received minimum two prior therapies for patients with relapsed or refractory metastatic disease 2020

10 GlaxoSmithKline (GSK) Blenrep Belantamab mafodotin-blmf Relapsed or refractory multiple myeloma in adults 2020, withdrawn on 22 Nov. 2022 in the US.

11 ADC Therapeutics Zynlonta Loncastuximab tesirine-lpyl Large B-cell lymphoma 2021

12 Seagen Inc Tivdak Tisotumab vedotin-tftv Recurrent or metastatic cervical cancer 2021

13 ImmunoGen Elahere Mirvetuximab soravtansine Platinum-resistant ovarian cancer 2022

北米の抗体薬物複合体市場の概要

北米の抗体薬物複合体（ADC）市場は、米国、カナダ、メキシコに基づいて分析されています。同地域の市場開拓の背景には、ADCの研究開発の増加、製品承認の増加、ADCに関する認知度の向上、事業者間の合併・提携・パートナーシップの増加があります。加えて、がんの罹患率が大幅に増加していることも、ADCの需要を拡大する主要因の1つです。

さらに、さまざまな地域で技術を拡大するために企業間の提携が拡大していることも、市場の成長を可能にしています。2023年8月、ImmunoGen, Inc.とTakeda Pharmaceutical Company Limitedは、ImmunoGen, Inc.のADC治療薬「ELAHERE」を日本で開発・販売することで提携しました。本提携契約に基づき、ImmunoGen, Inc.は、プラチナ製剤抵抗性卵巣がん治療薬「ELAHERE」のFDA加速承認取得時に契約一時金および追加金を受領します。また、武田薬品が日本における「ELAHERE」の売上高を通じて、一定の薬事・商業上のマイルストンおよび2桁のロイヤルティを達成した場合、Takeda Pharmaceutical Company Limitedは、ImmunoGen, Inc.に追加金を支払います。ただし、Immunogenは独占的製造権を保持し、日本での開発および商業化のために製品を供給します。その対価として、Takeda Pharmaceutical Company Limitedは薬事申請に関する全ての責任を負い、日本におけるELAHEREの独占的開発・販売権を有することになります。

北米の抗体薬物複合体市場の収益と2030年までの予測（金額）

北米の抗体薬物複合体市場セグメンテーション

北米の抗体薬物複合体市場は、技術、用途、流通チャネル、国によって区分されます。

北米の抗体薬物複合体市場は、技術別では、開裂性リンカーと非開裂性リンカーに二分されます。2022年には開裂性リンカーセグメントが大きなシェアを占めています。

用途別では、北米の抗体薬物複合体市場は血液がん、乳がん、卵巣がん、尿路上皮がん、その他に区分されます。2022年には乳がん分野が最大のシェアを占めています。

流通チャネル別に見ると、北米の抗体薬物複合体市場は病院薬局、小売薬局、オンライン薬局に区分されます。病院薬局セグメントが2022年に最大シェアを占めました。

国別に見ると、北米の抗体薬物複合体市場は米国、カナダ、メキシコに分類されます。2022年の北米の抗体薬物複合体市場は米国が支配的でした。

ADC Therapeutics SA、Pfizer Inc、Hoffmann-La Roche Ltd、ImmunoGen, Inc、GSK Plc、Gilead Sciences Inc、AstraZeneca Plc、Astellas Pharma Inc、RemeGen Co Ltd、Takeda Pharmaceutical Company Limitedは、北米の抗体薬物複合体市場で事業を展開している大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 市場の魅力

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の抗体薬物複合体市場 - 主要産業力学

  • 主な市場促進要因
    • 抗体薬物複合体開発のための戦略的パートナーシップの拡大
    • がん患者の増加
    • ADCに対するFDA承認の増加
  • 市場抑制要因
    • ADCの開発と商業化にかかる高コスト
  • 市場機会
    • ADC開発への投資の増加
  • 市場動向
    • ADCのパイプラインの増加
  • 影響分析

第5章 抗体薬物複合体市場：北米市場分析

  • 北米の抗体薬物複合体の市場収益（2017～2030年）

第6章 北米の抗体薬物複合体市場：収益・予測（～2030年）：技術別

  • 北米の抗体薬物複合体市場：収益シェア、2022年・2030年（%）：技術別
  • 開裂性リンカー
  • 非開裂性リンカー

第7章 北米の抗体薬物複合体市場：収益・予測（～2030年）：用途別

  • 北米の抗体薬物複合体市場：収益シェア、2022年・2030年（%）：用途別
  • 血液がん
  • 乳がん
  • 卵巣がん
  • 尿路上皮がん
  • その他

第8章 北米の抗体薬物複合体市場：収益・予測（～2030年）：流通チャネル別

  • 北米の抗体薬物複合体市場：収益シェア、2022年・2030年（%）：流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 北米の抗体薬物複合体市場：国別分析

    • 北米
      • 米国
      • カナダ
      • メキシコ

第10章 抗体薬物複合体市場：産業情勢

  • 有機的成長戦略
  • 無機的成長戦略
  • 各社の生産能力

第11章 企業プロファイル

  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd

第12章 付録

図表

List Of Tables

  • Table 1. North America Antibody Drug Conjugates Market Segmentation
  • Table 2. New Cancer Cases Worldwide, in 2020
  • Table 3. List of FDA-Approved ADCs
  • Table 4. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 5. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 6. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 7. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 8. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 9. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 10. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 11. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 12. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
  • Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
  • Table 15. Glossary of Terms, Antibody Drug Conjugates Market

List Of Figures

  • Figure 1. North America Antibody Drug Conjugates Market Segmentation, By Country
  • Figure 2. Key Insights
  • Figure 3. North America Antibody Drug Conjugates Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
  • Figure 6. North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • Figure 7. Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Non-Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 10. Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • Figure 16. Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. North America Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
  • Figure 20. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
  • Figure 21. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
目次
Product Code: BMIRE00029767

The North America antibody drug conjugates market was valued at US$ 3,659.81 million in 2022 and is expected to reach US$ 13,681.58 million by 2030; it is estimated to grow at a CAGR of 17.9% from 2022 to 2030.

Increasing FDA Approvals for ADCs Fuels the North America Antibody Drug Conjugates Market

According to an article, An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy, published in the National Library of Medicine in September 2021, there were eight approvals for ADC in 2017, and it increased to 11 in September 2021. The FDA has approved a few more ADCs, including Lumoxiti, till the end of November 2022. Worldwide, more than 50 biopharmaceutical companies are involved in developing ADCs. The companies have targeted mainly blood cancer and other cancer types, such as lung, bladder, and gynecological tumors. Additionally, in June 2021, Evercore, a US-based Investment Banking and Evercore ISI, estimated that by 2030, the companies will sell ADCs for over US$ 20 billion annually. The increasing approvals and commercialization of ADCs are leading to significant market growth. Below is a list of FDA-approved ADCs.

  • Table 1. List of FDA-Approved ADCs

Sr. No. Company Trade Name ADC Drug Cancer Type Approval Year

1 Pfizer/Wyeth Mylotarg Gemtuzumab ozogamicin Relapsed Acute Myelogenous Leukemia (AML) 2000; 2017

2 Seagen Genetics, Millennium/Takeda Adcetris Brentuximab vedotin Relapsed HL and Relapsed sALCL 2011

3 Genentech, Roche Kadcyla Trastuzumab emtansine HER2-positive Metastatic Breast Cancer (mBC) 2013

4 Pfizer/Wyeth Besponsa Inotuzumab ozogamicin Relapsed or Refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia 2017

5 Astrazeneca Lumoxiti Moxetumomab pasudotox Relapsed or refractory hairy cell leukaemia (HCL) in adults 2018

6 Genentech, Roche Polivy Polatuzumab vedotin-piiq Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 2019

7 Astellas/Seagen Genetics Padcev Enfortumab vedotin Metastatic urothelial cancer in adult who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy 2019

8 AstraZeneca/Daiichi Sankyo Enhertu Trastuzumab deruxtecan Metastatic HER2-positive breast cancer in adults, received two or more prior anti-HER2 based regimens 2019

9 Immunomedics Trodelvy Sacituzumab govitecan Metastatic triple-negative breast cancer (mTNBC) in adults, and patients received minimum two prior therapies for patients with relapsed or refractory metastatic disease 2020

10 GlaxoSmithKline (GSK) Blenrep Belantamab mafodotin-blmf Relapsed or refractory multiple myeloma in adults 2020, withdrawn on 22 Nov. 2022 in the US.

11 ADC Therapeutics Zynlonta Loncastuximab tesirine-lpyl Large B-cell lymphoma 2021

12 Seagen Inc Tivdak Tisotumab vedotin-tftv Recurrent or metastatic cervical cancer 2021

13 ImmunoGen Elahere Mirvetuximab soravtansine Platinum-resistant ovarian cancer 2022

North America Antibody Drug Conjugates Market Overview

The antibody drug conjugates (ADCs) market in North America is analyzed based on the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

Furthermore, growing partnerships among the companies to expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogens ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.

North America Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)

North America Antibody Drug Conjugates Market Segmentation

The North America antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the North America antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the North America antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the North America antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the North America antibody drug conjugates market is categorized into US, Canada, and Mexico. The US dominated the North America antibody drug conjugates market in 2022.

ADC Therapeutics SA, Pfizer Inc, Hoffmann-La Roche Ltd, ImmunoGen, Inc, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the North America antibody drug conjugates market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Antibody Drug Conjugates Market - Key Industry Dynamics

  • 4.1 Key Market Drivers:
    • 4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
    • 4.1.2 Rising Incidences of Cancer Cases
    • 4.1.3 Increasing FDA Approvals for ADCs
  • 4.2 Market Restraints
    • 4.2.1 High Cost of ADCs Development and Commercialization
  • 4.3 Market Opportunities
    • 4.3.1 Increasing Investments to Develop ADCs
  • 4.4 Market Trends
    • 4.4.1 Escalating Pipeline of ADCs
  • 4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - North America Market Analysis

  • 5.1 North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

  • 6.1 Overview
  • 6.2 North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • 6.3 Cleavable Linker
    • 6.3.1 Overview
    • 6.3.2 Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Non-cleavable Linker
    • 6.4.1 Overview
    • 6.4.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

  • 7.1 Overview
  • 7.2 North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • 7.3 Blood Cancer
    • 7.3.1 Overview
    • 7.3.2 Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Breast Cancer
    • 7.4.1 Overview
    • 7.4.2 Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Ovarian Cancer
    • 7.5.1 Overview
    • 7.5.2 Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Urothelial Cancer
    • 7.6.1 Overview
    • 7.6.2 Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 8.1 Overview
  • 8.2 North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Online Pharmacies
    • 8.5.1 Overview
    • 8.5.2 Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Antibody Drug Conjugates Market - Country Analysis

  • 9.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 9.1.1 Overview
    • 9.1.2 North America Antibody Drug Conjugates Market Breakdown, by Country Revenue (2022) (US$ Million)
    • 9.1.3 North America: Antibody Drug Conjugates Market, by Countries,2022 and 2030 (%)
      • 9.1.3.1 US
        • 9.1.3.1.1 Overview
        • 9.1.3.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.1.3 US: Antibody Drug Conjugates Market, by Technology
        • 9.1.3.1.4 US: Antibody Drug Conjugates Market, by Application
        • 9.1.3.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
      • 9.1.3.2 Canada
        • 9.1.3.2.1 Overview
        • 9.1.3.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.2.3 Canada: Antibody Drug Conjugates Market, by Technology
        • 9.1.3.2.4 Canada: Antibody Drug Conjugates Market, by Application
        • 9.1.3.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
      • 9.1.3.3 Mexico
        • 9.1.3.3.1 Overview
        • 9.1.3.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
        • 9.1.3.3.4 Mexico: Antibody Drug Conjugates Market, by Application
        • 9.1.3.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel

10. Antibody Drug Conjugates Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

  • 11.1 ADC Therapeutics SA
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Pfizer Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Hoffmann-La Roche Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 ImmunoGen, Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 GSK Plc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Gilead Sciences Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 AstraZeneca Plc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Astellas Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 RemeGen Co Ltd
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Takeda Pharmaceutical Co Ltd
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms